Enfamil Premature LIPIL
This article was originally published in The Tan Sheet
Executive Summary
New preterm infant formula contains same levels of docosahexaenoic acid, arachidonic acid as regular LIPIL, Mead Johnson says. Launching this month in 3 oz., ready-to-use bottles, formula will be distributed to hospitals, healthcare professionals and direct to consumers through a toll-free number. Mead announced July 9 FDA had no concerns regarding its premarket notification for the product. BMS division says formula's growth, development benefits for preterm infants are demonstrated by studies presented at Pediatric Academic Societies' annual meeting in May (1"The Tan Sheet" April 29, 2002, p. 22). Similac Advance marketer Ross Products says it also expects to launch fortified preterm formula upon agency clearance of its premarket notification. Abbott Labs' division's second quarter sales were flat at $515 mil., company announced July 11...
You may also be interested in...
DHA, ARA Benefit Preterm Infants, Research Shows; Formulas On Horizon
Infant formula fortified with docosahexaenoic acid (DHA) and arachidonic acid (ARA) provide significant growth benefits over non-fortified formula in preterm infants, study results indicate
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.